Heparin-induced thrombocytopenia

Review published in Ann Biol Clin (Paris) (2000)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Narrative reviewDesarrollo de fármacosEnsayos clínicosDepasse F, Samama MM · Annales de biologie clinique, 2000

Abstract

Heparin-induced thrombocytopenia is a threatening complication of heparin treatment. The physio-pathological mechanism is the production of antibodies, the most frequent target of which is the complex heparin-platelet factor 4. These antibodies may activate the coagulation and lead to venous or arterial thromboembolic manifestations. Clinical features as well as functional and immunological tests are used for the diagnosis. The treatment consists in discontinuing heparin administration and in setting up an alternative treatment for which two drugs are indicated in France: Orgaran and Refludan.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Indexed MeSH termsAntibody FormationAnticoagulantsChondroitin SulfatesDermatan SulfateHeparinHeparan SulfateHirudin TherapyHirudinsHumansRecombinant ProteinsThrombocytopenia

Resumen

French-language review of heparin-induced thrombocytopenia pathophysiology, diagnostics and treatment with Orgaran and Refludan (lepirudin) as alternative anticoagulants.

Por qué esto importa para la hirudoterapia

This review discusses heparin-induced thrombocytopenia (HIT) as a complication of heparin treatment, caused by antibodies against the heparin–platelet factor 4 complex that can activate coagulation and lead to thromboembolic events. The abstract states that treatment consists of discontinuing heparin and initiating alternative therapy, naming Orgaran and Refludan as two drugs indicated for this purpose in France. The relevance to ASH's domain is limited: the abstract identifies Refludan only by brand name and provides no information about its relationship to hirudin, leeches, or the leech secretome, so any hirudotherapy connection cannot be established from the abstract alone. The article's scope is a general review of HIT pathophysiology and management with only brief mention of named alternative agents and no experimental data or detail specific to Refludan.

Citación

[Heparin-induced thrombocytopenia].

Depasse F, Samama MM · Annales de biologie clinique, 2000

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug Pipeline Drug Development Direct Thrombin Inhibitors Clinical Evidence Clinical Applications Anticoagulation Compounds Hemostasis Otolaryngology

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026